Johnson & Johnson : 2023 Second-Quarter Press Release & Supp

FOR IMMEDIATE RELEASE



2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational...

Related Keywords

United States , Joaquin Duato , Biosense Webster , Exchange Commission , Receptor Antagonist Peptide In Development , Johnson Announces Launch Of Kenvue Inc , Roadshow , Women Health , Johnson , Consumer Health , Group To Develop Next Generation Therapies , Librexia Program , Abiomed , Interventional Solutions , Skin Health Beauty , Chief Executive , Operational Sales , Net Earnings , Pulmonary Hypertension , Infectious Diseases , General Surgery , Advanced Surgery , Current Reports , Quarterly Reports , Annual Reports , Marks First Approval Worldwide , Abiraterone Acetate , Action Tablet , Resistant Prostate Cancer , Track Designation , All Three Indications Under , Ischemic Stroke , Acute Coronary Syndrome , Submits New Drug Application , Tablet Combination Therapy , Pulmonary Arterial Hypertension , Earlier Treatment , Refractory Multiple , Reports First Results , Bacillus Calmette Gu , Inflammatory Bowel Disease Show Positive , Results Among Patients , Severely Active Ulcerative Colitis , Data Published , Highlight Scientific Advances , Transform Cancer Care , Showcasing Robust , Hematologic Malignancies , Solid Tumors , Demonstrate Potential Benefit , Pregnant Individuals , Early Onset Severe Hemolytic Disease , Announces Positive Topline Results , Only Oral , Antagonist Peptide , Moderate To Severeplaque Psoriasis , Clinically Meaningful Improvement , Progression Free Survival , Newly Diagnosed , Mutation Positivenon Small Cell , Johnson Announces Launch , Enters Worldwide Collaboration , License Agreement , Cellular Biomedicine , Develop Next Generation , Reported Sales , Euro Average Rate , Markets ,